Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 12;12:665147. doi: 10.3389/fimmu.2021.665147

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Wu, Xie, Wang, Li, Han, Qin, Zhang, Wu, Gao, Zhang, Wei, Liu and Jiao

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Combination of cytokines predicts survival more precisely in lung cancer patients with clinical benefit (CB) and no clinical benefit (NCB). (A) The accuracy of cytokine combination I was evaluated using the linear discriminant analysis (LDA). (B) Kaplan–Meier plots of progression-free survival (PFS, left) and overall survival (OS, right) of LDA-CB and LDA-NCB based on cytokine combination I. (C) The accuracy of cytokine combination II was evaluated using the LDA. (D) Kaplan–Meier plots of PFS (left) and OS (right) of LDA-CB and LDA-NCB based on cytokine combination II. (E) The ROC curve of 5-fold cross-validation for cytokine combination I. (F) The ROC curve of 5-fold cross-validation for cytokine combination II.